^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
Excerpt:
...- Hormone-receptor positive defined as estrogen receptor-positive and/or progesterone receptor-positive...
Trial ID:
Source:
Title:
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Excerpt:
...Patients ≥ 18 years of age with histologically, and radiographically confirmed non-metastatic ER-positive (defined as ≥30% of positive cells) and HER2-positive (defined as overexpression by immunohistochemistry (3+) or 2+ and positive by defined by fluorescence or dual in situ hybridization.) breast cancer with minimal tumor size over 2 cm (≥T2 lesion) to receive neoadjuvant chemotherapy recommended by the treating physician 2....
Trial ID:
Less C2 evidence
Source:
Title:
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Published date:
06/30/2022
Excerpt:
HER2-positive early BC patients given neoadjuvant chemotherapy with trastuzumab and pertuzumab....55 of 80 (71%) tumours were ER-positive. PCR occurred in 37 of 78 (46.3%; 95% CI: 35.3-57.2%) patients. 14 of 23 (60.8%) patients with ER-negative tumours achieved pCR; 23 of 55 (41.8%)....his data confirms the efficacy of neoadjuvant chemotherapy combined with dual HER2 directed therapy.
Secondary therapy:
Chemotherapy
DOI:
10.1155/2022/7146172
Source:
Title:
788291 - The Utility of MRI in Predicting Response of Lymph Nodes in HER2-positive and Triple-negative Breast Cancer to Combination Neoadjuvant Immunotherapy and Chemotherapy (NAICT) and Its Implications on Axillary Surgical Management Noeline Rajarajan1 , Robert Weinfurtner2 , John Kiluk2 , Catherine Lee2 , Brian Czerniecki2
Published date:
05/23/2020
Excerpt:
...13 ER+HER2+ patients treated with subcutaneous interferon gamma (IFN-γ) in combination with weekly paclitaxel with Trastuzumab and Pertuzumab...Patients with biopsy-proven nodal HER2-positive and triple-negative breast cancer treated with NAICT had an overall 65% axillary pCR...
Secondary therapy:
paclitaxel
Source:
Title:
Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice.
Published date:
05/16/2018
Excerpt:
All patients were treated with neoadjuvant therapy that included trastuzumab and pertuzumab...The study included 9 luminal B (ER+/Her2 3+) and 18 Her2 positive breast cancers ( Er- / HER 2 3+)....Out of 9 Luminal B, 4 had pCR (44, 4%), and 5 had partial response. (56%).
